

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-123)

GAVOCABTAGENE AUTOLEUCEL

PRONUNCIATION

gav" oh kab' ta jeen aw" toe loo' sel

THERAPEUTIC CLAIM

Treatment of mesothelin (MSLN)-positive cancer

PRODUCT DESCRIPTION

TC-210 T cells are genetically engineered autologous T cells that express a humanized anti-MSLN single-domain antibody, MH1, fused to the TCR CD3 ϵ subunit, which is then incorporated into the endogenous TCR complex upon expression (MSLN CD3 ϵ -T cell receptor fusion construct).

DIAGRAM

Genetic map of MSLN CD3 ϵ -T cell receptor fusion construct:



Table of features:

Annotation	Description	Position
5' LTR	Long terminal repeats R-U5-PBS	1..200
psi packaging	RNA target site for packaging by nucleocapsid.	292..336
gag partial	Precursor structural protein of the lentiviral particle containing Matrix, Not translated	337..689
RRE	Rev Response Element	712..1479
cPPT	Central polypurine tract	1486..1663
EF-1alpha promoter	Promoter of human 'elongation factor-1 alpha gene'	1678..2870
Transgene TRuC	CDS (coding sequence) of the fusion MH1/CD3 ϵ	2886..3899
GMCSFRa Leader	Leader of granulocyte-macrophage colony-stimulating factor receptor alpha	2886..2951
MH1 sdAb	Humanized anti-mesothelin single-domain antibody binder	2952..3284
A3(G4S)3LE Linker	Flexible linker	3285..3344
CD3 ϵ	Residues 23 to 207 of human CD3 ϵ	3345..3899
WPRE	Woodchuck hepatitis virus post-transcriptional regulatory element	3920..4500
3'PPT	3' polypurine tract	4507..4577
3' LTR SIN	Long terminal repeats Δ U3-R	4578..4729

TRADEMARK

None as of yet

SPONSOR

TCR2 Therapeutics

CODE DESIGNATIONS

TC-210 T cells

UNII

NP6CFH3G8H

WHO NUMBER

11437

SCS